Antibody glycosylation in COVID-19

• Published in: Glycoconjugate journal Vol. 39; no. 3; pp. 335 - 344
• Main Authors: Pongracz, Tamas, Vidarsson, Gestur, Wuhrer, Manfred
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2022; Springer Nature B.V
• Subjects: Antibodies; Biochemistry; Biomedical and Life Sciences; Coronaviruses; COVID-19; Glycosylation; Immune response; Immunoglobulin G; Immunoglobulins; Life Sciences; Mini Review; Pathology; Severe acute respiratory syndrome coronavirus 2; Vaccination; COVID-19; IgG glycosylation; SARS-CoV-2; Glycomics, biomarker; Antibody glycosylation
• ISSN: 0282-0080; 1573-4986; 1573-4986
• DOI: 10.1007/s10719-022-10044-0

Antibody glycosylation has received considerable attention in coronavirus disease 2019 (COVID-19) infections and recently also in vaccination. Antibody glycosylation and in particular immunoglobulin G1 fucosylation levels influence effector functions and are therefore key parameters for assessing the efficacy and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directed immune responses. This review article summarizes and interprets recent research into antibody glycosylation in COVID-19. Experimental approaches for analyzing the glycosylation of SARS-CoV-2-directed antibody responses are evaluated. The pronounced dynamics, effector functions, clinical utility, and regulation of antibody glycosylation in COVID-19 are assessed. Future research on the role of antibody glycosylation in COVID may cover the glycosylation of other antibody classes beyond immunoglobulin G, the regulation of antibody glycosylation, and the role of non-canonical antibody receptors in determining effector functions. Graphical abstract